Verrica says post-hoc Phase 3 analysis shows YCANTH clears molluscum regardless of disease duration
VRCA•Company says findings support broader use
Verrica said the findings support broader use versus watchful waiting, potentially expanding treating-physician confidence and eligible patient capture.
VP-315 poster repeats Phase 2 exploratory data
The company also scheduled an encore poster on VP-315. Verrica said it repeats previously presented Phase 2 exploratory data suggesting immune-driven shrinkage in untreated basal cell carcinoma lesions.
YCANTH Phase 3 analysis to be presented at dermatology conferences
Verrica Pharmaceuticals said a post-hoc Phase 3 analysis of YCANTH will be presented publicly for the first time at upcoming dermatology conferences in September 2026.
The company said the analysis shows strong clearance of molluscum regardless of how long patients have had the disease.
